N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis
N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis have?
N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis has 24 citations in the OpenAlex counts ScholarIQ stores.
When was N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis published?
N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis has 2024 year in the ScholarIQ index.
What is the open-access status of N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis?
N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis has hybrid oa status in the ScholarIQ index.
What is the DOI of N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis?
The DOI for N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis is on the source record.
What is the PMID of N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis?
The PMID for N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis is on the source record.
What is the OpenAlex record for N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis?
The OpenAlex for N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis is on the source record.